All News

Men who are receiving androgen deprivation therapy treatment for prostate cancer experience higher levels of fatigue and depression when compared to men who are not receiving treatment and who have no history of cancer.

Lynparza demonstrates a significantly longer duration of survival compared Xtandi or Zytiga for men with metastatic prostate cancer, one study found.

Over the last 30 years, cases of childhood liver cancer have increased in the United States, Australia and a Canadian province.

In the wake of the COVID-19 pandemic, many of the serious medical difficulties patients with cancer face has been brought to the forefront for healthcare as a whole. But we can learn lessons from these challenges and find a stronger path forward.

Researchers observed the benefit of adhering to a Mediterranean diet in all men, in addition to non-White men and those without diabetes.

With two different COVID-19 vaccines out there, it's important for patients with cancer to understand the different side effects for both. We help break down what patients and survivors can possibly expect.

In an interview with CURE®, Dr. Lawrence An discusses how expressive writing can be a tool to reduce stress in patients with cancer.

On social media, CURE® recently asked its readers to share if they have participated in support groups, and, if so, how they benefitted from the experience.

A cancer survivor laments the inability for a comforting hand during COVID-19.

Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.

A caregiver discusses the challenges of always waiting to hear "the cancer is back."

The FDA has lifted a partial clinical hold on a phase 2 trial evaluating a novel therapy in patients with acute myeloid leukemia following an allogenic stem cell transplant.

Generations of cancer leads to the risk that must be addressed head-on, but the lessons we can take from our own family members who have had cancer is valuable to pass on.

In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.

The FDA’s fast track designation for ARX788 to treat patients with advanced or metastatic HER2-positive breast cancer who have received at least one previous anti-HER2-based treatment in the metastatic setting, may open the doors to an accelerated approval.

Life is fleeting, and cancer survivors and caregivers understand that perhaps better than most.

From one leukemia survivor organizing essential blood drives for patients with cancer as COVID-19 delays hit, to a kindergarten teacher handling a recurrence of ovarian cancer by continuing to teach her students through Zoom, here’s what’s happening in the cancer landscape this week.

In an interview with CURE®, the “Felicity” and “Scandal” actor spoke about his experience as a caregiver to his mother, and why women should not just watch and wait for their ovarian cancer to recur.

After being diagnosed with the BARD1 gene and undergoing a preventative double mastectomy, Nina Garcia shares her story to raise awareness and offer hope for other women.

In a recent trial, the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal women with lymph node-positive, HR-positive, HER2-negative breast cancer.

A caregiver discusses with her granddaughter the cancer diagnosis and treatment of a loved one.

A roundup of liver cancer news and updates that occurred in 2020 patients with cancer may have missed.

The FDA has not yet reached a decision on an application for the approval of a CAR-T cell therapy product for the treatment of relapsed/refractory large b-cell lymphoma and, according to Bristol Myers Squibb, a new action date for the decision has not been set.

The FDA based its decision on data that demonstrated that the novel therapy in combination with Tecentriq induced a higher overall response to therapy compared to Tecentriq alone in patients with PD-L1-positive non-small cell lung cancer.

Choosing to forego breast reconstruction after breast cancer surgery can cause one to feel like the lone ranger, but that feeling doesn’t last long, especially upon the discovery of an entire flattie tribe.

The FDA granted a priority review to the supplemental new drug application for Lorbrena for the firstline treatment of ALK-positive metastatic non-small cell lung cancer.

A roundup of some skin cancer news and updates that occurred in 2020 that patients may have missed.

Patients with advanced or metastatic kidney cancer treated with the novel drug combination achieved a median progression-free survival of 9.2 months compared to 9.3 months among patients who received Cabometyx with a placebo.